4yr
Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer-A Literature Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35877254/
1 Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N3M5, Canada. 2 Department of Medicine, Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON M5S1A1, Canada. Free PMC article Free PMC article 1 Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N3M5, Canada.
Conclusions: Classifying the risk category assists in deciding the treatment route and its optimal duration. Tailoring the breadth of ET hinges on a wide array of factors to be appraised for each individualized case, including weighing its benefits and harms.
Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer-A Literature Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35877254/
1 Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N3M5, Canada. 2 Department of Medicine, Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON M5S1A1, Canada. Free PMC article Free PMC article 1 Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N3M5, Canada.